Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
3.0
Journals
Diagnostics
Special Issues
Advances in Cancer Pathology and Diagnosis
share announcement

Advances in Cancer Pathology and Diagnosis

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 1106

Special Issue Editor

Dr. Lorenzo Memeo

E-Mail Website
Guest Editor
Pathology Unit, Department of Experimental Oncology, Mediterranean Institute of Oncology, 95029 Catania, Italy
Interests: gastrointestinal tumors; endocrine tumors; urological tumors; breast tumors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Since the advent of personalized treatment in oncology, histopathology has become even more central to the diagnostic process in oncological patients. A correct and exhaustive diagnosis, not only in terms of the histological classification of tumors but also in the field of biomarker assessment, now represents the cornerstone of correct treatment planning in oncology.

In addition, the widespread use of molecular classification in tumors means that pathologists can now access a more detailed diagnosis, to help oncologists select the best treatment options.

Furthermore, the addition of modern techniques, including digital pathology and AI applications, is currently re-shaping workflows in pathology labs, in combination with classical pathology instruments such as morphology and immunohistochemistry.

In this Special Issue, we would like to focus on new methods for the classification of tumors, predictive biomarker evaluation in tumors (mainly using immunohistochemistry but also using NGS or RT-PCR), and applications of digital pathology and AI in cancer diagnosis. Interesting and informative case reports are also welcome.

Dr. Lorenzo Memeo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • histopathology
  • histological classification
  • cancer biomarkers
  • digital pathology
  • AI applications
  • next-generation sequencing
  • real-time PCR

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 518 KiB  
Article
Prebiopsy Magnetic Resonance Imaging Followed by Combination Biopsy for Prostate Cancer Diagnosis Is Associated with a Lower Risk of Biochemical Failure After Treatment Compared to Systematic Biopsy Alone
by Shima Tayebi, Samuel Tremblay, Jason Koehler, Alon Lazarovich, Fernando Blank, Wei-Wen Hsu, Sadhna Verma and Abhinav Sidana
Diagnostics 2025, 15(6), 698; https://doi.org/10.3390/diagnostics15060698 - 12 Mar 2025
Viewed by 684
Abstract
Background: Prostate cancer (PCa) diagnosis remains a complex field of study. Multiparametric magnetic resonance imaging (mpMRI) technology presents opportunities to enhance diagnostic precision. While recent advances in imaging and biopsy techniques show promise, the oncological implications of prebiopsy magnetic resonance imaging (MRI) and [...] Read more.
Background: Prostate cancer (PCa) diagnosis remains a complex field of study. Multiparametric magnetic resonance imaging (mpMRI) technology presents opportunities to enhance diagnostic precision. While recent advances in imaging and biopsy techniques show promise, the oncological implications of prebiopsy magnetic resonance imaging (MRI) and combination biopsy (ComBx) are not fully understood. This retrospective study evaluates the potential clinical impact of prebiopsy MRI and ComBx on PCa treatment outcomes. Methods: We conducted a comprehensive review of treatment-naïve patients undergoing prostate biopsy and subsequent radiation therapy (RT) or radical prostatectomy at the University of Cincinnati Health Center (2014–2020). Patients were categorized into two cohorts: those with prebiopsy mpMRI and ComBx versus those with systematic biopsy (SBx) alone. Patients with prostate-specific antigen (PSA) > 20 ng/mL were excluded. Biochemical recurrence (BCR) was defined as PSA ≥ 0.2 ng/mL post-prostatectomy or ≥2 ng/mL above nadir post-RT. Results: This study included 518 patients (189 SBx, 329 ComBx) with a median follow-up of 19.1 months. Median patient ages were 65.9 years (SBx) and 64.6 years (ComBx). The overall BCR rate was 10% with significantly lower rates in the ComBx group compared to SBx (6.4% vs. 16.4%, p < 0.001). Multivariable Cox regression analysis showed patients undergoing prebiopsy mpMRI with ComBx were 63% less likely to experience BCR (HR: 0.37, 95%CI 0.20–0.70, p = 0.002). Conclusions: Prebiopsy MRI followed by ComBx demonstrated lower BCR rates, suggesting improved PCa diagnosis and risk stratification. These findings highlight the potential of advanced imaging and biopsy techniques to benefit the management of PCa. Further longitudinal studies are needed to confirm the long-term clinical benefits of this approach. Full article
(This article belongs to the Special Issue Advances in Cancer Pathology and Diagnosis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop